Bli medlem
Bli medlem

Du är här


Karolinska Development – sale of own shares to cover social security fees related to 2012 incentive program

Karolinska Development – sale of own shares to cover social security fees
related to 2012 incentive program

STOCKHOLM - December 16, 2015. The Board of Directors of Karolinska Development
has decided - within the authorization from the Annual General Meeting on May
20, 2015 - to sell a maximum of 20,000 Series B shares to cover the cost of
social security fees related to the 2012 employee incentive program.

The sale will be made from December 16, 2015 to May 24, 2016, which is the day
before the Annual General Meeting 2016. The sale of shares shall take place on
NASDAQ OMX Stockholm and may only occur at a price within the price interval
registered at each time for the share. The share price interval is the price
interval between the highest buying price and the lowest selling price.

The purpose of the sale is to cover charges in the form of social security fees
that relate to the PSP 2012 incentive program which was approved at the Annual
General Meeting on May 23, 2012. Prior to the above decision, Karolinska
Development holds 239,285 Series B shares.

For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail:

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail:


About Karolinska Development AB
Karolinska Development AB is an investment company focused on identifying
medical innovation and investing in the creation and growth of companies
developing these assets into differentiated products that will make a
difference to patients’ lives and provide an attractive return on investment.

Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes in
the Nordic region. The Company aims to build companies around scientists who
are leaders in their fields, supported by experienced management teams and
advisers, and co-funded by specialist international investors, to provide the
greatest chance of success.

Karolinska Development has established a portfolio of 12 companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.

The Company is led by a team including investment professionals with strong
venture capital backgrounds, experienced company builders and entrepreneurs,
with access to a strong global network.

For more information, please visit

This constitutes information that Karolinska Development AB (publ) (Nasdaq
Stockholm: KDEV) is legally obliged to publish under the Securities Market Act
and/or the Financial Instruments Trading Act.

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.